PublQedso Fumes SSSR Abstract = Send to: ve sua. 2000 2917129188 ot 10115) vEesuG 2010.05 001, Fou 20102, Erythromycin as a prokinetic agent: risk factors. Bethel", Chavpiat 8, Mabwt JY. © Author information *Servee de phamacko,hiptal de la Crok« Rousse, 103 Grande Rue de la Crok« Rousse, Lyon codex 04, France. Abstract Erythromycin (ER) san antibitic wth proknete acthty. This propery has led 10s clicel use to improve gastic emptying in patients wth gestroparesi Severl papers have reported the ettectiveness of ERin sich patents; awever fay of these studies have bean ell-concictes ‘mathodlogially with evaluation of eral endpoints and tei asus ave often contvadetoy. A barack analysts porto prsergon of ER ‘should take into account the numerous medication interactions of this dug as well asthe prevention of carcovascular complications, most notably torsade de pointes and cardiac arest The aim ofthis paper was to provide new insights into these adverse events and allow for betterinfrmed proceion. Fisk prevention requis preseriptlon guidelines and effective communication among surgeons, anesthesologists and pharmacists Copycght () 2010 Elsevier Masson SAS. Al ights reserved. Pawo, 20855050 Pubes nero or MEDLINE] He 5 Publication Types, MeSH Terms, Substances. ¥ LinkOut- more resources ¥